MK-5172 - CAS 1350514-68-9
Catalog number: 1350514-68-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C38H50N6O9S
Molecular Weight:
766.9
COA:
Inquire
Targets:
HCV
Description:
In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose.
Purity:
>98%
Related CAS:
1350514-68-9 (free); 1350462-55-3 (hydrate)
Appearance:
Solid powder
Synonyms:
(33R,35S,91R,92R,5S)-5-(tert-butyl)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamide; MK-5172; MK 5172; MK5172; Grazoprevir trade name: Zepatier‎
MSDS:
Inquire
InChIKey:
OBMNJSNZOWALQB-NCQNOWPTSA-N
InChI:
1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1
Canonical SMILES:
O=C([C@H]1N2C([C@H](C(C)(C)C)NC(O[C@]3([H])C[C@@]3([H])CCCCCC4=NC5=CC=C(OC)C=C5N=C4O[C@](C2)([H])C1)=O)=O)N[C@@]6(C(NS(=O)(C7CC7)=O)=O)[C@H](C=C)C6
1.New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
Sorbera MA;Friedman ML;Cope R J Pharm Pract. 2017 Jun;30(3):359-365. doi: 10.1177/0897190016632128. Epub 2016 Feb 22.
Due to the intimate relationship between liver and kidney disease in hepatitis C virus (HCV) infection, treatment options for HCV-positive patients at any stage of chronic kidney disease (CKD) are essential. The availability of second-generation, direct-acting antiviral (DAA) combinations has allowed for the advent of interferon-sparing treatment regimens with shorter durations and minimal side effects. While many of the second-generation DAAs are principally metabolized by the hepatic system, dosing in severe renal impairment (creatinine clearance [CrCl] <30 mL/min) or dialysis has remained questionable due to limited experience. New evidence regarding the use of these agents in renal impairment continues to become available, as real-world experience with these treatment regimens is reported. Simeprevir, ledipasvir, paritaprevir, ombitasvir, dasabuvir, and daclatasvir have data to suggest safety in end-stage renal disease. While safety and efficacy with sofosbuvir remains uncertain, data are now available to support utilizing a dose adjustment when glomerular filtration rates are <30 mL/min. Upcoming regimens grazoprevir/elbasvir and daclatasvir/asunaprevir/beclavubir may provide further options for patients with advanced kidney disease, and ongoing studies will continue to provide guidance for this unique patient population.
2.Elbasvir/Grazoprevir: First Global Approval.
Keating GM Drugs. 2016 Apr;76(5):617-24. doi: 10.1007/s40265-016-0558-3.
A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic HCV genotype 1 or 4 infection. This article summarizes the milestones in the development of elbasvir/grazoprevir leading to this first global approval for chronic HCV genotype 1 or 4 infection.
3.Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
de Lédinghen V;Laforest C;Hézode C;Pol S;Renault A;Alric L;Larrey D;Métivier S;Tran A;Jézéquel C;Samuel D;Zoulim F;Tual C;Pailhé A;Gibowski S;Bourlière M;Bellissant E;Pawlotsky JM Clin Infect Dis. 2018 Mar 19;66(7):1013-1018. doi: 10.1093/cid/cix916.
Background: ;Failure to achieve sustained virological response (SVR) with hepatitis C virus (HCV) direct-acting antiviral (DAA)-based regimens is commonly associated with emergence of resistance-associated substitutions (RASs). Retreatment of patients who failed prior DAAs remains challenging. The aim of this prospective and randomized study was to evaluate the efficacy (primary endpoint: SVR 12 weeks after end of treatment [SVR12]) and safety of sofosbuvir + grazoprevir/elbasvir + ribavirin for 16 or 24 weeks in patients who had failed to achieve SVR on previous NS5A- or NS3-based therapy and with evidence of RASs at failure.;Methods: ;Patients were chronically infected with HCV genotype 1 or 4. Most of them had advanced fibrosis or compensated cirrhosis (liver stiffness 5.8-48.8 kPa).;Results: ;All patients achieved HCV RNA below the lower limit of quantification (either target detected [unquantifiable] or target not detected) during treatment. SVR12 was achieved by 25 of 26 patients. The only patient who did not reach SVR was a patient who died, but HCV RNA was negative at this time (5 weeks after stopping treatment). No patient discontinued treatment because of adverse events or virological failure.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HCV Products


CAS 1009734-33-1 HZ-1157

HZ-1157
(CAS: 1009734-33-1)

HZ-1157 is an inhibitor of hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) protease.

CAS 690270-29-2 Balapiravir

Balapiravir
(CAS: 690270-29-2)

Balapiravir is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase. It is the tri-isobutyrate ester prodr...

CAS 1216941-48-8 Paritaprevir

Paritaprevir
(CAS: 1216941-48-8)

Paritaprevir could inhibit viral phosphoprotein NS5A and is significant to viral replication and other activities. It also has been found to have potential effe...

CAS 442666-98-0 Anguizole

Anguizole
(CAS: 442666-98-0)

Anguizole is a small molecule inhibitor of HCV replication and alters NS4B's subcellular distribution.

CAS 1441674-54-9 Ledipasvir acetone

Ledipasvir acetone
(CAS: 1441674-54-9)

Ledipasvir is an inhibitor of hepatitis C virus NS5A.

CAS 263870-19-5 APC-6336

APC-6336
(CAS: 263870-19-5)

APC-6336 is a Hepatitis C virus NS3 protein inhibitor.

CAS 940908-79-2 R-7128

R-7128
(CAS: 940908-79-2)

R-7128 is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, with activity across all HCV genotypes. It i...

CAS 254435-95-5 Alisporivir

Alisporivir
(CAS: 254435-95-5)

Alisporivir, also known as DEB-025, a non-immunosuppressive cyclosporine A derivative, is acyclophil ininhibitor molecule with potent anti-hepatitis C virus (HC...

Chemical Structure

CAS 1350514-68-9 MK-5172

Quick Inquiry

Verification code

Featured Items